With the FDA nod, Alecensa becomes the second molecularly targeted therapy to move into the adjuvant setting for non-small cell lung cancer.
The health regulor has required related updates to other sections of the label such as warnings and precautions, ...
The new label for Alecensa makes it the first targeted treatment available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.
The Food and Drug Administration is signing off on a first prescription digital treatment to help with depression.